KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Invested Capital (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Invested Capital for 7 consecutive years, with $18.7 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 3.96% to $18.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.7 billion through Dec 2025, up 3.96% year-over-year, with the annual reading at $18.7 billion for FY2025, 3.96% up from the prior year.
  • Invested Capital hit $18.7 billion in Q4 2025 for Royalty Pharma, up from $18.6 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $18.7 billion in Q4 2025 to a low of $15.7 billion in Q1 2021.
  • Historically, Invested Capital has averaged $17.1 billion across 5 years, with a median of $17.3 billion in 2021.
  • Biggest five-year swings in Invested Capital: skyrocketed 118.61% in 2021 and later dropped 10.33% in 2023.
  • Year by year, Invested Capital stood at $17.3 billion in 2021, then fell by 4.05% to $16.6 billion in 2022, then fell by 2.54% to $16.2 billion in 2023, then increased by 10.7% to $18.0 billion in 2024, then increased by 3.96% to $18.7 billion in 2025.
  • Business Quant data shows Invested Capital for RPRX at $18.7 billion in Q4 2025, $18.6 billion in Q3 2025, and $17.5 billion in Q2 2025.